Page 149 - Read Online

Stambo et al. Hepatoma Res 2017;3:141-8 Hepatoma Research
DOI: 10.20517/2394-5079.2017.12
www.hrjournal.net
Original Article Open Access

Response rates of hepatocellular carcinoma

and hepatic colorectal cancer metastases

to drug eluting bead regional liver therapy

Glenn W. Stambo , Deborah Cragan
2
1
1 Department of Vascular and Interventional, Florida Hospital, Tampa, FL 33614, USA.
2 College of Public Health, University of South Florida, Tampa, FL 33612, USA.

Correspondence to: Dr. Glenn W. Stambo, Department of Vascular and Interventional, Florida Hospital, 7171 N. Dale Mabry Highway, Tampa, FL
33614, USA. E-mail: gstambo64@yahoo.com
How to cite this article: Stambo GS, Cragan D. Response rates of hepatocellular carcinoma and hepatic colorectal cancer metastases to drug eluting
bead regional liver therapy. Hepatoma Res 2017;3:141-8.
ABSTRACT
Article history: Aim: The purpose of this study was to evaluate and compare how hepatocellular carcinoma
Received: 27-03-2017 (HCC) and colorectal metastases respond to LC Bead chemoembolization using doxorubicin
Accepted: 19-05-2017 and irinotecan. Methods: The authors report their experience with doxorubicin and irinotecan
Published: 12-07-2017 eluting beads to treat 13 patients with primary HCC and 25 patients with colorectal metastases
over a 1-year period at a single community based oncology practice. Within the colorectal
Key words: cancer group they compared irinotecan eluting beads to doxorubicin eluting beads. Results:
Angiography, Nine of the 11 (81.8%) doxorubicin treated HCC patients had either complete response or
transarterial chemoembolization, partial response. All of the HCC lesions showed reduction in size and tumor enhancement and
drug eluting beads, 10/11 (91%) HCC patients were alive at 24 months post treatment. Fisher’s exact test revealed
hepatocellular carcinoma, that among the 22 with colorectal metastases for whom follow-up data were available, those
doxorubicin, 11 who were treated with doxorubicin were significantly more likely to demonstrate complete
irinotecan or partial response compared to the 11 in the irinotecan treated group (P < 0.001). Conclusion:
Overall, HCC and colon metastasis patients clearly demonstrated the effectiveness of drug
eluting beads with 91% of the HCC patients alive 24 months after treatment.

INTRODUCTION 2 years. Surgery is the definitive treatment for isolated
lesions while systemic chemotherapy has been the
Primary and secondary malignancies of the liver are standard treatment for unresectable liver neoplasms. [1-3]
very common accounting for more than 530,000 new Most lesions are not surgically resectable at the time
cases per year. Hepatoma and secondary neoplasms of diagnosis due to their extensive tumor burden.
[1]
of the liver are expected to increase as the incidence Treatment strategies for unresectable liver cancer are
of hepatitis C continues to spread throughout the different for hepatocellular carcinoma (HCC), other
world. Colorectal metastases to the liver and primary primary liver tumors, and metastatic liver cancer. For
malignant hepatic neoplasms have a poor prognosis example, transarterial chemoembolization (TACE) may
with dismal survival rates of 31% at 1 year and 26% at be the standard for HCC but chemotherapy is still the

Quick Response Code:
This is an open access article distributed under the terms of the Creative Commons Attribution-
NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work
non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: service@oaepublish.com

© 2017 OAE Publishing Inc. www.oaepublish.com 141